BioCentury
ARTICLE | Clinical News

INT131: Phase IIb data

October 5, 2009 7:00 AM UTC

The double-blind, U.S. and Mexican Phase IIb INT131-007 trial in 366 Type II diabetics showed that oral INT131 met the primary endpoint of significantly decreasing HbA1c from baseline vs. placebo at 24 weeks (p<0.0001). InteKrin said the compound's efficacy was "comparable" to that shown by active-comparator Actos pioglitazone, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) markets in the U.S. and co-markets with Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) in various countries in Europe, Asia and other regions. ...